Stock Market & Financial News
Bitcoin falls below $80,000 as hot US payrolls revive Fed hike risk
The 162,000 jobs gain lifted yields and the dollar, but the first selloff did not hold uniformly.
USELESS Flips BONK Intraday as Solana Memecoin Rally Hands Trader $3.2M Profit
USELESS surged more than 60% as its market cap topped $200 million, while trader Unipcs' 15.9 million-token position climbed above $4 million.
Zscaler Falls 4% as FY2027 Growth Guidance Overshadows Earnings Beat; CrowdStrike Slips, Palo Alto Holds Steady
Cybersecurity software is under pressure again Friday morning after Zscaler (NASDAQ:ZS | ZS Price Prediction) issued fiscal 2027 growth guidance that overshadowed a clean fourth-quarter beat, and peers are drifting with it.
ZS -0.19% FB Financial's Southern Expansion and Buybacks Drive Analyst Optimism
The banking company is a year into absorbing a major southern acquisition while earnings surge, loans grow, and aggressive buybacks are boosting shareholder returns.
SO +0.2% 
Apple's Ternus era begins as Nvidia bets on the whole AI stack
It's officially the Ternus era at Apple.
AAPL +0.94% 
Brasilagro Cia Brasileira De Propriedades Agricolas Q4 Earnings Call Highlights
Brasulagro Cia Brasileira De Propriedades Agricolas NYSE: LND reported a net loss of BRL 90 million for its 2025/2026 harvest year ended June 30, 2026, compared with a BRL 138 million loss in the prior-year period, as weaker sugarcane and cotton results offset stronger grain production.
LND +0.87% 
Quanex Building Products Q3 Earnings Call Highlights
Quanex Building Products NYSE: NX reported third-quarter fiscal 2026 sales of $501.8 million, up 1.3% from $495.3 million a year earlier, as higher pricing offset the effects of tariff reimbursements to customers. The company said volumes were flat, pricing increased about 3%, and tariff refunds reduced revenue by approximately 2%.
NX +0.76% 
Ionis Pharmaceuticals Wins FDA Approval for First Alexander Disease Treatment
Ionis Pharmaceuticals NASDAQ: IONS said the U.S. Food and Drug Administration has approved ZANVASTRO as the first and only disease-modifying treatment for Alexander disease, an ultra-rare, progressive neurological disorder caused by pathogenic variants in the GFAP gene.
IONS -0.84% 
Pendle launches on Robinhood Chain with sNET market
Pendle has launched its first yield-trading market on Robinhood Chain, giving sNET holders access to fixed and variable yield positions until the market matures on Sept. 17, 2026.
Marvell Rises 6% as Beaten-Down AI Silicon Bounces, Qualcomm Barely Budges
AI silicon is catching a bid Friday morning while the broader U.S. market leaks lower, and the leadership is coming squarely from the names beaten down over the past few sessions.
MRVL +2.31% 
U.S. Global Investors, Inc. (GROW) Q4 2026 Earnings Call Prepared Remarks Transcript
U.S. Global Investors, Inc. (GROW) Q4 2026 Earnings Call Prepared Remarks Transcript
GROW +0.7% 
Alpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
Alpha Tau is positioned for a transformative inflection point with potentially groundbreaking GBM data expected before year-end and pancreatic shortly after. Two out of first three GBM patients achieved a complete response (CR), essentially unheard of in GBM. Alpha Tau is still severely underknown to investors, adding to its re-rating potential.
DRTS +1.31% 
Can Strategic Acquisitions Strengthen TransDigm's Growth?
TDG is expanding its proprietary aerospace portfolio through disciplined acquisitions that bolster aftermarket capabilities and long-term growth.
TDG -0.19% 
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
TMO +0.03% 
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
Summit Therapeutics stock jumps 17% after ivonescimab showed a significant overall survival benefit over Keytruda in a China phase III lung cancer study.
SMMT +1.17% 
Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
MED is shifting toward metabolic health with its 3.0 strategy, targeting broader growth, greater efficiency and a return to profitability.
MED +1.66% 
Implied Volatility Surging for FTAI Aviation Stock Options
Investors need to pay close attention to FTAI stock based on the movements in the options market lately.
FTAI +0.56% 
Volaris Reports Decrease in Consolidated Load Factor for August
VLRS saw August traffic rise 15.4% year over year, while capacity grew 15.8%, pushing consolidated load factor down 0.3 points to 84.4%.
VLRS -0.08% 
PayPal's BNPL and Credit Growth: Can It be a Further Upside Driver?
PYPL is expanding financial services, with BNPL, credit and debit products fueling growth and deepening engagement across its customer base.
PYPL -0.4% 
Can Coursera's $85M Synergy Plan Unlock More Upside for Investors?
COUR's $85M synergy target and rising margins could reshape its profitability, but softer normalized revenues keep execution in focus.
COUR -0.49% 
NTAP Q1 Earnings Beat Estimates on Hybrid, Public Cloud Revenue Growth
NetApp's record Q1 FY27 results show strong Hybrid and Public Cloud momentum as AI demand and modernization drive growth.
NTAP +6.9% 
WDC Stock's Big Rally: Buy, Sell, or Hold After a 70% 6-Month Surge?
Western Digital's AI-driven storage growth, rising HDD pricing and expanding margins strengthen its case, but lofty expectations make the stock a closer call.
WDC -12.76% 
Philips Shares AI Tool Data for Mitral Regurgitation Assessment at ESC
PHG's AI-powered 3D Auto CFQ shows stronger agreement with cardiac MRI than 2D PISA, supporting its cardiovascular ultrasound strategy.
PHG +0.29% 
Will Nebius Group's Mega AI Deals Power Its 2027 Growth Story?
NBIS is building toward 2027 growth as multibillion-dollar AI cloud deals, premium pricing and major capacity expansion strengthen its revenue outlook.
NBIS +4.7% 
ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
AbbVie's etentamig meets key phase III goals in multiple myeloma, improving response rates and progression-free survival versus standard therapies.
ABBV +0.65% 
MAMA Q2 Earnings Beat Estimates on Retail Expansion, Bay Shore Gains
MAMA tops Q2 estimates as revenues jump 55%, supported by branded-item ramps, broader customer penetration and the Bay Shore acquisition.
MAMA +0.39% 
Can TROW's New Securitized Income ETF Boost Fixed-Income Growth?
T. Rowe Price Group, Inc. TROW is expanding its active exchange-traded fund (ETF) offerings with the launch of the T. Rowe Price Securitized Income ETF (TSCZ).
TROW +0.01% 
Reasons to Hold HealthEquity Stock in Your Portfolio for Now
HQY's growth is driven by rising HSA assets and AI-led efficiencies, while cybersecurity risks remain a key concern.
HQY +0.64% 
Smith & Nephew keeps Jefferies 'buy' despite H2 growth scepticism
Smith & Nephew PLC (LSE:SN) drew a cautious assessment from Jefferies on Friday, with the broker maintaining its 'buy' rating despite investor scepticism over execution and a reduced financial year 2026 guidance. Shares in the company traded around 1,059p as Jefferies held its 1,500p price target, citing an all-time low valuation of 12 times estimated 2027 earnings alongside lumpy operational execution.
SN +1.59% 
Adobe stock drops on surprise CEO transition
Adobe Inc (NASDAQ:ADBE) shares were down 6.5% on Friday after the company announced a major leadership shake-up, naming Anil Chakravarthy as its next chief executive to succeed longtime CEO Shantanu Narayen. Chakravarthy, currently president of Adobe's digital experience business, will take over as CEO effective December 1, the start of Adobe's fiscal 2027.
ADBE -1.59% 
